Barings Continues to Support the Growth of Xeinadin, an Exponent Portfolio Company
Barings, one of the world’s leading investment managers, today announced its role as sole lender in incremental delayed draw facilities for Xeinadin Group (“Xeinadin”), a portfolio company of Exponent Private Equity (“Exponent”). Barings has supported Xeinadin since 2022, when Xeinadin entered a strategic partnership with Exponent, providing senior facilities across the capital structure.
Xeinadin is a leading business advisory and accountancy firm, providing a full suite of services to SMEs, entrepreneurs, corporations, partnerships and not-for-profit organisations. Today, it comprises 2,000+ professionals serving 120,000+ clients and is one of the Top 20 largest accountancy firms in the UK and Ireland. Xeinadin continues to grow organically and through acquisition, selectively acquiring businesses that share their local, personal approach and commitment to helping clients achieve their business goals.
About Barings
Barings is a $421+ billion* global asset management firm that partners with institutional, insurance, and intermediary clients, and supports leading businesses with flexible financing solutions. The firm, a subsidiary of MassMutual, seeks to deliver excess returns by leveraging its global scale and capabilities across public and private markets in fixed income, real assets and capital solutions.
*As of December 31, 2024
About Exponent
Established in 2004 with a presence in London, Dublin and Amsterdam, Exponent is a leading private equity firm, investing in mid-market companies headquartered across Europe (UK, Ireland, Benelux and Nordics). Exponent has a distinctive approach, central to which is identifying the potential in corporate, family or founder-owned businesses.
Exponent has raised more than €3 billion to date. A selection of Exponent’s current and past investments include market leading businesses such as Trainline, Moonpig, Ambassador Theatre Group, H&MV, Isio and Quorn Foods.